Epinastine is used for the prevention of itching associated with allergic conjunctivitis. It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Hydrocodone | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Epinastine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Epinastine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Mirtazapine | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Orphenadrine | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Pramipexole | Epinastine may increase the sedative activities of Pramipexole. |
| Ropinirole | Epinastine may increase the sedative activities of Ropinirole. |
| Rotigotine | Epinastine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Epinastine. |
| Sodium oxybate | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Thalidomide | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Epinastine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Epinastine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Epinastine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Epinastine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Epinastine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Epinastine. |
| Atazanavir | Epinastine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Epinastine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | Epinastine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | Epinastine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | Epinastine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | The serum concentration of Epinastine can be decreased when it is combined with Dabrafenib. |
| Dasatinib | Epinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Epinastine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexmethylphenidate | The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Epinastine. |
| Erlotinib | Epinastine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Epinastine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Epinastine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Epinastine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Epinastine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Epinastine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Epinastine. |
| Nelfinavir | Epinastine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nilotinib | Epinastine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazopanib | The therapeutic efficacy of Pazopanib can be decreased when used in combination with Epinastine. |
| Rilpivirine | Epinastine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Epinastine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | Epinastine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Epinastine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Epinastine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Epinastine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Epinastine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Epinastine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Epinastine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Epinastine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Epinastine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Epinastine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Epinastine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Epinastine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Epinastine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Epinastine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Epinastine is combined with (S)-Warfarin. |
| Mirabegron | The serum concentration of Epinastine can be increased when it is combined with Mirabegron. |
| Mesalazine | The therapeutic efficacy of Mesalazine can be decreased when used in combination with Epinastine. |
| Ethanol | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Epinastine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Epinastine. |
| Sertraline | The risk or severity of adverse effects can be increased when Epinastine is combined with Sertraline. |
| Desvenlafaxine | The serum concentration of Epinastine can be increased when it is combined with Desvenlafaxine. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Citalopram. |
| Sibutramine | The risk or severity of adverse effects can be increased when Epinastine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Epinastine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Epinastine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Epinastine is combined with Milnacipran. |
| Seproxetine | The risk or severity of adverse effects can be increased when Epinastine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Epinastine is combined with Indalpine. |
| Alaproclate | The risk or severity of adverse effects can be increased when Epinastine is combined with Alaproclate. |
| Lisdexamfetamine | The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Epinastine. |
| Amphetamine | Amphetamine may decrease the sedative activities of Epinastine. |
| Phentermine | Phentermine may decrease the sedative activities of Epinastine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Epinastine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Epinastine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Epinastine. |
| MMDA | MMDA may decrease the sedative activities of Epinastine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Epinastine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Epinastine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Epinastine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Epinastine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Epinastine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Epinastine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Epinastine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Epinastine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Epinastine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Epinastine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Epinastine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Epinastine. |